Non-selective beta blockers inhibit angiosarcoma cell viability and increase progression free- and overall-survival in patients diagnosed with metastatic angiosarcoma

@inproceedings{Amaya2018NonselectiveBB,
  title={Non-selective beta blockers inhibit angiosarcoma cell viability and increase progression free- and overall-survival in patients diagnosed with metastatic angiosarcoma},
  author={Clarissa N. Amaya and Mariah Perkins and Andres Belmont and Connie Herrera and Arezo Nasrazadani and Alejandro Vargas and Thuraieh Khayou and Alexa Montoya and Yessenia Ballou and Dana C Galv{\'a}n and Alexandria Rivas and Steven L. Rains and Luv Patel and Vanessa Ortega and Christopher Lopez and William Chow and E B Dickerson and Brad A Bryan},
  booktitle={Oncoscience},
  year={2018}
}
Patients with metastatic angiosarcoma undergoing chemotherapy, radiation, and/or surgery experience a median progression free survival of less than 6 months and a median overall survival of less than 12 months. Given the aggressive nature of this cancer, angiosarcoma clinical responses to chemotherapy or targeted therapeutics are generally very poor… CONTINUE READING